🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT06886724
Starting soon Not applicable

Investigating the Efficacy of Probiotics in Enhancing Gastrointestinal and Immunological Health

NCT06886724 · tracked via the Priya Life Science China tracker
Sponsor
Wecare Probiotics Co., Ltd.
Phase
Not applicable
Started
2025-03-10
Last updated
2025-03-20

Condition(s) studied

Intestinal and Lmmune Function Lmproved

Investigational drug(s) / intervention(s)

ProbioticPlacebo

Probiotic: The trial period of this study lasts for 2 months (8 weeks), during which each participant will have 3 visits (at month 0, month 1, and month 2).

Placebo: The trial period of this study lasts for 2 months (8 weeks), during which each participant will have 3 visits (at month 0, month 1, and month 2).

Study summary

Evaluate the effectiveness and safety of Ligilactobacillus salivarius LS97 as a food supplement compared to a placebo in improving intestinal and immune functions in healthy adults.

Eligibility

Sex
ALL
Min age
18 Years
Max age
45 Years
Healthy volunteers
Accepted
Inclusion Criteria: 1. Willing to undergo 3 follow-up visits during the intervention period 2. Be willing to provide blood, urine and stool samples 2 times during the intervention period 3. Good eyesight, can read and write, can wear glasses 4. Have good hearing and be able to hear and understand all instructions during the intervention Exclusion Criteria: 1. Digestive diseases, mainly gastrointestinal diseases (celiac disease, ulcerative colitis, Crohn's disease) 2. Have a serious neurological condition (epilepsy, stroke, severe head trauma, meningitis in the last 10 years, brain surgery, brain tumor prolonged coma - not including general anaesthesia) 3. Have received/are receiving treatment for the following mental disorders: alcohol/drug/substance abuse dependence, schizophrenia psychosis, bipolar disorder 4. Take medication for depression or low mood 5. Internal organ failure (heart, liver or kidney failure, etc.) 6. Have received radiation or chemotherapy in the past 7. have undergone a general anesthesia procedure/procedure within the past three years, or plan to undergo a general anesthesia procedure/procedure within the next 3 months during this trial period 8. Have had hepatitis (hepatitis B, hepatitis C), HIV or syphilis in the past

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Xu fei Zhengzhou Henan

More Wecare Probiotics Co., Ltd. trials in China

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06886724 on ClinicalTrials.gov ↗ ← All trials in China